$ISRG (Intuitive Surgical, Inc.)

$ISRG {{ '2016-09-29T13:51:06+0000' | timeago}} • Announcement

$ISRG and Shanghai Fosun Pharmaceutical Co. Ltd. have entered into a JV to develop and sell robotic-assisted catheter-based medical devices. The JV will initially produce products targeting early diagnosis and cost-effective treatment of lung cancer. The companies will contribute up to $100MM as required by the JV.

$ISRG {{ '2017-07-21T12:26:16+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$ISRG {{ '2017-07-20T20:21:13+0000' | timeago}} • Announcement

In 2Q17, $ISRG's service revenue rose 11% to $142MM while instrument and accessory revenue jumped 17% to $398MM. Intuitive Surgical ended the second quarter with $3.4Bil in cash, cash equivalents, and investments.

$ISRG {{ '2017-07-20T20:16:13+0000' | timeago}} • Announcement

In 2Q17, revenue for $ISRG jumped 13% to $756MM while net income soared 20% to $222MM or $5.77 per diluted share. Non-GAAP net income was $228MM or $5.95 per diluted share, with systems revenue increased by approximately 7% to $216MM.

$ISRG {{ '2017-05-30T20:51:18+0000' | timeago}} • Announcement

$ISRG's new da Vinci X Surgical System received FDA clearance in the US. The da Vinci X System will provide surgeons and hospitals with access to some of the most advanced robotic-assisted surgery technology at a lower cost.

$ISRG {{ '2017-04-18T22:04:46+0000' | timeago}} • Webcast

$ISRG stated that on the da Vinci X, the instruments are going to be similar to the Xi. Additionally, instruments on X are the same family as the Xi. On additional instruments, the company has a portfolio of instruments it's working on and $ISRG is expanding its stapler line, to be a full line sapling system.

$ISRG {{ '2017-04-18T21:34:45+0000' | timeago}} • Webcast

$ISRG said that on the procedure guidance, the company expects 2017 procedure growth to be driven by US general surgery and international procedure. On the Australia work, which was on the flexible robotics platform, they are in patient follow up now. The company expects them to be presenting publicly in the fall.

$ISRG {{ '2017-04-18T21:00:54+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical, Inc. Earnings AlphaGraphics: Q1 2017 highlights

$ISRG {{ '2017-04-18T20:26:37+0000' | timeago}} • Announcement

For 1Q17, $ISRG's Instruments and Accessories revenue grew 18.22% YoY to $380.8MM, helped by nearly 18% growth in da Vinci procedure volume. Service revenue grew by 12.61% to $140.2MM, while Systems revenue for the quarter rose by 3.58% to $153.2MM from a year ago.

$ISRG {{ '2017-04-18T20:22:23+0000' | timeago}} • Announcement

Medical devices company $ISRG reported higher 1Q17 earnings, helped by higher revenue. Net income for the quarter rose 31.81% to $179.8MM or $4.67 per share from $136.4MM or $3.54 per share a year ago. Revenue grew 13.4% YoY to $674.2MM. Excluding items, $ISRG earned $5.09 per share.

$ISRG {{ '2017-04-18T12:04:26+0000' | timeago}} • Announcement

$ISRG said that equity awards, approved by the Compensation Committee of the BoD, which consists entirely of Independent Directors, were made to 57 new employees. The equity awards were granted under $ISRG 2009 Commencement Incentive Plan, which the board adopted for the granting of equity awards to new employees.

$ISRG {{ '2017-02-14T12:30:20+0000' | timeago}} • Announcement

$ISRG said that equity awards, approved by the Compensation Committee of the BoD, which consists entirely of Independent Directors, were made to 92 new employees. The equity awards were granted under the 2009 Commencement Incentive Plan, which the Board adopted for the granting of equity awards to new employees.

$ISRG {{ '2017-01-24T22:18:13+0000' | timeago}} • Webcast

$ISRG said that in 2017, the company expects its pro forma gross profit margin to be in the range of 69-71% of net revenue. The company also expects to grow pro forma 2017 operating expenses between 15-18% above 2016 levels.

$ISRG {{ '2017-01-24T22:10:09+0000' | timeago}} • Webcast

$ISRG ended 4Q16 with cash and investments of $4.8Bil, up from $4.6Bil as of Sept. 30, 2016. This increase was mainly driven by cash generated from operations and proceeds from stock option exercises. During 4Q16, the company repurchased 55,000 shares for $34MM.

$ISRG {{ '2017-01-24T21:48:52+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical Earnings AlphaGraphics: Q4 and FY16 Highlights

$ISRG {{ '2017-01-24T21:28:33+0000' | timeago}} • Announcement

For 3Q16, $ISRG's Instruments and Accessories revenue rose 18.64% YoverY to $386.3MM, helped by growth in U.S. general surgery procedures and worldwide urologic procedures. Service revenue grew by 12.06% to $134.7MM, while Systems revenue for the quarter rose by 2.25% to $235.9MM from a year ago.

$ISRG {{ '2017-01-24T21:23:55+0000' | timeago}} • Announcement

Medical devices company $ISRG posted higher 4Q16 earnings, helped by higher revenue. Net income for the quarter rose 7.36% to $204MM or $5.13 per share from $190MM or $4.99 per share a year ago. Revenue grew 11.88% YoverY to $756.9MM. Excluding items, $ISRG earned $6.09 per share.

$ISRG {{ '2016-10-18T22:04:52+0000' | timeago}} • Webcast

$ISRG is seeing encouraging trends in hernia in terms of rates of procedure adoption and surgeon retention. The utilization within the existing surgeon population as they continue to do more procedures has been a strong point in the way the technology has been adopted.

$ISRG {{ '2016-10-18T21:52:31+0000' | timeago}} • Webcast

$ISRG said looking into 2017, margins are likely to be impacted by factors such as introduction of new products, manufacturing efficiencies, geographical mix and also the mix between systems and instruments and accessories.

$ISRG {{ '2016-10-18T21:45:07+0000' | timeago}} • Webcast

$ISRG said the technology for the new biopsy platform is based on computer-controlled catheters along with special sensing technologies and image analysis. The company's first clinical interest is in biopsying lung cancers which it believes is important globally and particularly important in China. In this regard, the Fosun JV is relevant.

$ISRG {{ '2016-10-18T21:33:26+0000' | timeago}} • Webcast

For 2016, $ISRG expects procedure growth of 14-15% versus 2015. Pro forma gross profit margin is expected to be 71.5% of net revenue. Pro forma Opex is expected to grow 13-14% versus 2015. Non-cash stock compensation expense is expected to be $170-180MM. Other income is expected to be about $33MM. $ISRG expects tax rate to be 26.5-28.5%.

Recent Transcripts

AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
POOL (Pool Corp.)
Thursday, July 20 2017 - 3:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
PKOH (Park-Ohio Holdings Corp.)
Tuesday, May 9 2017 - 2:00pm
STE (Steris Plc)
Tuesday, May 9 2017 - 2:00pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
SNN (Smith & Nephew plc)
Friday, May 5 2017 - 7:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
AMED (Amedisys Inc.)
Wednesday, May 3 2017 - 3:00pm
MTRN (Materion Corporation)
Friday, April 28 2017 - 1:00pm

AlphaGraphics you may like